Skip to main content
Clinical Trials/NCT03859180
NCT03859180
Completed
N/A

A Pilot Study for a Self-Managed Intervention for Anxiety in Parkinson's Disease

Virginia Commonwealth University1 site in 1 country28 target enrollmentMarch 15, 2019

Overview

Phase
N/A
Intervention
Not specified
Conditions
Parkinson Disease
Sponsor
Virginia Commonwealth University
Enrollment
28
Locations
1
Primary Endpoint
Parkinson Anxiety Scale (PAS)
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

A mixed methods randomized controlled feasibility and acceptability study will be conducted to determine the effects of a self-managed, focused breathing intervention on anxiety in persons who have been diagnosed with Parkinson's disease.

Detailed Description

This study is being conducted to determine the feasibility and acceptability of using focused breathing as a self managed, non-pharmacologic intervention for anxiety experienced by those with Parkinson's disease. Participants meeting eligibility criteria will be randomized to either an intervention or control group. Those in the intervention group will be taught how to perform focused breathing and asked to practice it twice daily for six weeks for a minimum of four minutes each time. Anxiety, depressive symptoms, sleep, self-efficacy and quality of life with be measured in participants in both the intervention group before beginning to practice focused breathing as well as in the control group. After six weeks of practice the same measurements will be collected from the intervention group. Additionally, intervention participants will participate in a brief interview at the end of their six weeks of practice. Control group participants will be taught how to perform focused breathing six weeks at the end of a six week wait-period, following collection of data using the aforementioned measures..

Registry
clinicaltrials.gov
Start Date
March 15, 2019
End Date
November 11, 2019
Last Updated
6 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Clinical diagnosis of Parkinson's disease
  • Hoehn \& Yahr I, II, \& III
  • Self report or clinical diagnosis of anxiety
  • Ability to speak and read English

Exclusion Criteria

  • Montreal Cognitive Assessment scores less than 26, indicating cognitive impairment
  • Persons under the age of 18 are excluded from this study

Outcomes

Primary Outcomes

Parkinson Anxiety Scale (PAS)

Time Frame: 6 weeks following onset of focused breathing twice daily practice.

This is an 11 question, Likert scale which includes the following responses: Not at all or never Very mild or rarely Mild, or sometimes Moderate, or often Severe, or (nearly) always. The tool is has 3 sub-scales designed to measure persistent anxiety, episodic anxiety, and avoidance behavior in Parkinson's disease. It will be administered pre and post intervention for the experimental group and pre and post enrollment for the control group. Scores from 36-48 could indicate the possibility of an anxiety disorder and the need for a clinical evaluation.

Secondary Outcomes

  • Parkinson's Quality Scale-8 (PDQ-8)(6 weeks)
  • General Self Efficacy Scale (GSES)(6 weeks)
  • Geriatric Depression Scale(6 weeks)
  • Parkinson Sleep Scale - 2 (PSS-2)(6 weeks)

Study Sites (1)

Loading locations...

Similar Trials